Downgrading Defibrillators: When Less is More for Heart Patients
"Discover a novel approach to safely transition from a CRT-D to a CRT-P device, optimizing cardiac care and extending device lifespan."
As medical technology advances, the ability to tailor treatments to individual patient needs becomes increasingly crucial. One area where this is particularly evident is in the management of cardiac rhythm devices. Traditionally, patients with heart failure and a risk of sudden cardiac death are often implanted with a cardiac resynchronization therapy-defibrillator (CRT-D). These devices combine the functions of a pacemaker and a defibrillator, providing both rhythm support and protection against life-threatening arrhythmias.
However, as patients' conditions evolve, the need for the defibrillator function may diminish. For instance, some patients experience significant improvement in their heart function with CRT, reducing their risk of ventricular tachyarrhythmias. In such cases, continuing with a CRT-D may expose them to unnecessary risks, such as inappropriate shocks and complications associated with device replacements. The decision to replace or downgrade a CRT-D system upon reaching battery depletion requires careful consideration.
A recent study highlights a novel approach to address this challenge: downgrading a CRT-D to a CRT-P (cardiac resynchronization therapy-pacemaker) by utilizing the existing defibrillator lead in a pacemaker system. This method offers a less invasive and potentially safer alternative to complete device replacement, optimizing cardiac care while minimizing patient risk. This article delves into the details of this innovative technique, exploring its benefits, limitations, and implications for patients and healthcare providers.
CRT: Benefits and Limits
Cardiac resynchronization therapy (CRT) has been used in clinical practice for more than 20 years, progressing from small, uncontrolled studies to multiple randomized controlled trials. For appropriately selected heart-failure patients, CRT can reduce morbidity and mortality, reverse left-ventricular remodeling, and improve quality of life. Biventricular pacing is described as the standard treatment for patients with reduced left-ventricular ejection fraction and electrical dyssynchrony, but about one in three patients does not respond. A review of CRT upgrades and downgrades also notes that small sample size, a single-centre design, and prespecified patient characteristics limit the evidence on whether CRT represents remission or complete recovery.
How CRT Became Established
CRT’s concept originated in Europe in the early 1990s, and its initial approval for advanced heart failure came in 2001. By 2014, CRT was described as an accepted treatment for heart failure with impaired left-ventricular function and a wide QRS complex. It had become a realistic option even for patients with mild heart failure, whereas advanced heart failure had previously left cardiac transplantation as the only option described by the review. A 2020 review characterized CRT as the only known non-pharmacologic heart-failure therapy to improve cardiac function, functional capacity, and survival while reducing cardiac workload and hospitalization rates in chronic systolic heart failure with conduction-system disease.
The Case for Downgrading: Identifying Patients Who Benefit
The decision to downgrade from a CRT-D to a CRT-P is not one to be taken lightly. It requires a thorough evaluation of the patient's clinical history, current condition, and individual risk factors. Several factors may indicate that a patient is a good candidate for downgrading. One of the primary considerations is the absence of ventricular tachyarrhythmias. If a patient has not experienced any life-threatening arrhythmias since receiving their CRT-D, the need for the defibrillator function may be reassessed.
- Absence of ventricular tachyarrhythmias
- Improvement in left ventricular ejection fraction (LVEF)
- Older age and frailty
- Patient preference for reduced interventions
Residual Risk and Uneven Response
CRT does not benefit everyone: a 2026 review notes that some patients show no clinical improvement or reverse remodeling after implantation, with challenges including suboptimal patient selection and limitations in characterizing conduction disease. Downgrading a CRT-D to a CRT-P may leave some residual arrhythmic risk: one retrospective study reported subsequent appropriate ICD therapy in 8.2% of patients whose ejection fraction improved to at least 45% and who had no ICD therapy after one year. Among “super-responders,” whose ejection fraction improved to at least 50%, the reported two-year risk of ventricular tachycardia or ventricular fibrillation was 1.5%. A separate report argues that when a device needs replacement, implanting a larger, more expensive defibrillator solely to keep its therapies turned off may be unnecessary.
The Future of Cardiac Device Management
The innovative approach of downgrading CRT-Ds to CRT-Ps using existing leads represents a significant step forward in cardiac device management. By carefully selecting patients and utilizing existing technology, healthcare providers can optimize patient outcomes, reduce unnecessary interventions, and extend the lifespan of implanted devices. As technology advances and our understanding of cardiac physiology deepens, expect even more personalized and tailored approaches to cardiac rhythm management, improving the lives of patients worldwide.
A Decision at Device Replacement
CRT is effective for approximately two-thirds of recipients, while about one-third remain non-responders, according to a review exploring reasons for variable outcomes. For patients being considered for an upgrade to CRT, a 2023 article notes that long-term outcome data remain scarce. Device selection at replacement is described as a complex decision that should take account of a patient’s history and demographics. Together, these sources point to the importance of weighing individual response and available long-term evidence when considering device choices.
Downgrade Decisions in Follow-Up
Some people with a CRT-D survive long enough to need battery replacement, at which point defibrillator therapy may no longer be necessary for some patients who have had significant clinical improvement. In a follow-up study of patients downgraded from CRT-D to CRT-P, no significant tachyarrhythmias were detected in the downgraded group, although three events were observed in the CRT-D group. The study cautioned that a small residual risk of arrhythmic events remains and recommended making downgrade decisions case by case. Separately, a real-world study compared outcomes after CRT-D in a large private-practice cardiology setting with those in the COMPANION multicenter trial, reflecting interest in how trial outcomes translate to routine care.